---
title: "Denali Therapeutics (DNLI) Receives a Buy from UBS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289921157.md"
description: "UBS analyst Michael Yee maintained a Buy rating on Denali Therapeutics (DNLI) with a $25 price target. While Yee holds a 2-star rating, the broader analyst consensus for DNLI is a Strong Buy with an average price target of $35."
datetime: "2026-06-16T12:36:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289921157.md)
  - [en](https://longbridge.com/en/news/289921157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289921157.md)
generator: "portal-rs"
---

# Denali Therapeutics (DNLI) Receives a Buy from UBS

In a report released today, Michael Yee from UBS maintained a Buy rating on Denali Therapeutics, with a price target of $25.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Yee is a 2-star analyst with an average return of 0.4% and a 43.55% success rate. Yee covers the Healthcare sector, focusing on stocks such as Pfizer, Oruka Therapeutics, and Biogen.

Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $35.00.

### Related Stocks

- [DNLI.US](https://longbridge.com/en/quote/DNLI.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ORKA.US](https://longbridge.com/en/quote/ORKA.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)

## Related News & Research

- [B. Metzler seel. Sohn & Co. AG Buys New Stake in Denali Therapeutics Inc. $DNLI](https://longbridge.com/en/news/296694335.md)
- [Goldman Sachs Remains a Buy on Denali Therapeutics (DNLI)](https://longbridge.com/en/news/293392778.md)
- [Alliance Global Partners Sticks to Their Buy Rating for Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/297544479.md)
- [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md)
- [Spero Therapeutics files $300M mixed securities shelf](https://longbridge.com/en/news/297380989.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**